- $306M Net Income: Cypherpunk reported a staggering $306 million net income in Q3 2026, driven by Zcash mining and crypto derivatives.
- 13.1% Hashrate Control: The company now controls approximately 13.1% of the total Zcash network hashrate, with plans to expand to 25%.
- 341,858.75 ZEC Held: Cypherpunk owns 2.01% of the total circulating Zcash supply, aiming to hold at least 5% over time.
Experts would likely conclude that Cypherpunk's pivot from biotech to Zcash mining highlights the volatile yet lucrative potential of digital asset treasuries, raising concerns about network centralization and regulatory risks.
Inside Cypherpunk’s $306M Pivot From Failing Biotech to Zcash Giant
CAMBRIDGE, Mass. – November 16, 2026 – In what may be the most jarring corporate metamorphosis of the decade, a company once dedicated to curing cancer has abandoned its clinical trials to mine privacy cryptocurrencies. Cypherpunk Technologies Inc., formerly known as Leap Therapeutics, reported its third-quarter financial results today, revealing a staggering $306 million net income. Yet, this nine-figure profit did not stem from a breakthrough oncology treatment or a massive licensing deal. Instead, it is the product of an aggressive, Winklevoss-backed pivot into Zcash mining and an accounting anomaly tied to digital asset derivatives.
For those tracking the shifting tides of modern capital, the transformation of this Nasdaq-listed entity offers a stark reflection of current market incentives. Traditional biotechnology requires decades of slow-burn research, regulatory hurdles, and immense capital expenditure with binary outcomes. In contrast, digital asset treasuries offer immediate liquidity and, as demonstrated today, the potential for massive paper profits overnight. Cypherpunk’s latest earnings report is a masterclass in this new financial alchemy.
The Ultimate Corporate Pivot
Just a year ago, Leap Therapeutics was struggling. Following an endpoint miss in the Phase 2 DeFianCe study for its lead cancer drug candidate, sirexatamab, the firm faced a bleak future of dwindling cash reserves and skeptical investors. Enter Winklevoss Capital. Through a $58.88 million private placement, the firm orchestrated a radical rebirth. The oncology pipelines were sidelined, the ticker symbol was changed to CYPH, and the company began executing a strategy to corner the Zcash market.
The operational shift materialized rapidly. In August 2026, Cypherpunk acquired a massive fleet of Bitmain Antminer Z15 Pro machines from Moria Mining—an affiliate of Winklevoss Treasury Investments—for $33.33 million, paid entirely in pre-funded warrants.
"The launch of Cypherpunk Mining in August was transformative, as it enabled the production of ZEC alongside our purchases and contributes to the security of the Zcash network," said Douglas E. Onsi, President and Chief Executive Officer of Cypherpunk Technologies, in today's earnings release. "As we hold the ZEC we mine, we translated our Zcash flow into $9.9 million in recorded revenue. The average fair value of the mined ZEC was more than $1,100, while our hosting cost to mine one ZEC was approximately $104."
Paper Millions and the Reality of Crypto Accounting
While a $306 million net income figure commands attention, forensic accountants and market analysts are quick to point out the mechanics behind the curtain. The reality of Cypherpunk's profitability is heavily dependent on the volatile swings of the cryptocurrency market rather than pure operational cash flow.
During the company's first 44 days of mining operations, the fleet achieved an impressive 95% uptime, minting 8,967.29 ZEC and generating $9.9 million in non-cash mining revenue. However, the vast majority of the quarter's net income was driven by a $330.8 million non-cash unrealized gain on an embedded derivative. This massive mark-to-market gain reflects the explosive price action of Zcash, which surged from $400.09 at the end of June to $1,414.56 by September 30.
Under the Financial Accounting Standards Board's updated crypto asset accounting guidance (ASU 2023-08), entities must measure crypto assets at fair value, with changes recognized directly in net income. While this provides transparency into the current value of treasury holdings, it also injects extreme volatility into quarterly earnings. Financial observers note that these "paper millions" can evaporate just as quickly as they appear, binding the fate of equity shareholders directly to the whims of the altcoin market.
"The quarter marked a major milestone for Cypherpunk, and we are already planning for significant continued growth," stated Will McEvoy, Chief Investment Officer of Cypherpunk. "With 341,858.75 ZEC held, representing 2.01% of the total circulating supply, we continue to execute on our objective of holding at least 5% of the ZEC supply over time."
The 25% Hashrate Threat: Corporate Centralization vs. Privacy
Cypherpunk’s aggressive accumulation strategy raises profound existential questions for the Zcash network. Zcash, built on the memory-hard Equihash algorithm, was originally designed to resist industrial-scale ASIC mining and maintain a decentralized network of independent node operators. Today, a single publicly traded corporation threatens to upend that ethos.
As of mid-November, Cypherpunk controls approximately 13.1% of the total Zcash network hashrate. But the company is not stopping there. In September, Cypherpunk entered into a letter of intent with Bitmain for up to $30 million in next-generation Zcash mining machines. Upon delivery in mid-2027, this expansion aims to capture approximately 25% of the total network hashrate.
Blockchain policy analysts warn that this level of corporate concentration is antithetical to the foundational principles of privacy coins. While a 25% hashrate does not cross the 51% threshold required to execute direct network attacks or double-spend transactions, it grants unprecedented influence over block validation and protocol governance. If a single U.S.-regulated entity controls a quarter of the mining power and over 2% of the circulating supply, the network's resilience against censorship or regulatory pressure is severely compromised.
Discarding the Legacy Pipeline
Left in the wake of this digital gold rush are the remnants of Leap Therapeutics' scientific endeavors. The company has initiated a strategic process to identify a path forward for its oncology assets, including sirexatamab and FL-501. The options on the table include a partnership, out-licensing, or a complete spin-off to an independent entity.
However, biotech industry insiders note that divesting assets following a high-profile Phase 2 endpoint miss is a grueling endeavor. Pharmaceutical giants rarely pay a premium for clinical candidates with compromised efficacy data, meaning these legacy assets will likely be offloaded at a steep discount, if a buyer can be found at all.
Ultimately, Cypherpunk Technologies stands as a monument to the current era of capital allocation. When the grueling, high-stakes pursuit of medical innovation falters, the market offers a lucrative, albeit highly volatile, escape hatch in the form of digital asset mining. Whether this Winklevoss-engineered pivot represents the future of corporate treasury management or a temporary anomaly fueled by a crypto bull run remains to be seen, but for now, the ASICs are humming, and the paper profits are soaring.
Topics & Related
Quarterly Earnings
Net Income
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →